Company intelligence / Profile preview

PolyMedix, Inc.

Wayne, Pennsylvania, United Statespolymedix.com ↗

Ownership: Private
Development stage: Other

Overview

PolyMedix was a clinical-stage biotechnology company developing small-molecule drugs that mimic the activity of host defense proteins for infectious diseases and innate immunity disorders. Its lead compound Brilacidin demonstrated safety and efficacy in a Phase 2a trial for ABSSSI caused by Staphylococcus aureus (including MRSA), outperforming the control arm. Another program targeted anticoagulant reversal with PMX‑60056. The company filed for bankruptcy and its assets—including nine compounds—were acquired by Cellceutix Corporation in September 2013.[1][5]

Therapeutic areas: OncologyCardiovascularInfectious Diseases
Modalities: Small molecules (non-peptide mimetics of host defense proteins)Polymeric antimicrobials (PolyCides)
Industry: Biotech

Beyond the preview

Go deeper on PolyMedix, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolyMedix, Inc..